Arbutus Biopharma Corp
Company Stats
- Market Cap
- $945.7M
- as of Sep 30, 2026
- Shares Outstanding
- 197.8M
- Free Float
- 65.1%
Income Statement
- Revenue
- $14.1M
- Operating Income
- -$38.2M
- Net Income
- -$33.5M
- EBITDA
- -$37.8M
- Revenue Growth, 3Y
- -28.8%
- FCF Margin, 3Y Avg
- -604.9%
- FCF Margin, Worst Year
- -1053.8%
Cash Flow
- Free Cash Flow
- -$39.6M
- FCF Yield
- -4.2%
- Owner FCF Yield
- -4.9%
Balance Sheet
- Cash & Equivalents
- $18.0M
Returns & Capital
- SBC, 3Y Avg
- $8.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $14.1M | -$39.6M | -281.5% |
| FY2024 | $6.2M | -$65.0M | -1053.8% |
| FY2023 | $18.1M | -$86.9M | -479.3% |
| FY2022 | $39.0M | -$35.9M | -91.9% |
| FY2021 | $11.0M | -$68.3M | -622.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 30, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges